ReviewInternational journal of molecular sciences2021
Biomarkers for Cancer Cachexia: A Mini Review.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- Gene Ontology (GO)-Driven Inference of Candidate Proteomic Markers Associated with Muscle Atrophy Conditions.Molecules (Basel, Switzerland) · 2022Pooled it
- Trial
- Activatable NIR-II photoacoustic probes for cancer imaging and imaging-guided therapy.Bioactive materials · 2026Review
- Blood test trend versus single threshold abnormality to discriminate cancer from non-cancer in patients with unexpected weight loss: A retrospective cohort study.PLoS medicine · 2026Article
- Low Muscle Density Is Associated with Morbidity and Systemic Inflammation in Colorectal Cancer, Independent of Tumor Factors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- BMP4 derived from human gastrointestinal carcinoma cells impairs myogenic differentiation: A possibleInternational journal of oncology · 2026Article
- The Secretome of a Cachexia-Inducing Lung Tumor Impairs Mitochondrial Function and Skeletal Muscle Differentiation.Cancers · 2026Article
- Baseline Body Composition Characteristics and Overall Survival in Young Women with Breast Cancer: Matched Case-Control Study Nested Within a Cohort.Tomography (Ann Arbor, Mich.) · 2026Article
- Withaferin A Attenuates Angiotensin II-Induced Right Ventricular Dysfunction and Fibrosis.International journal of molecular sciences · 2026Article
- Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.Frontiers in nutrition · 2026Article
- Machine Learning-Based Identification of Blood Biomarkers that Distinguish Precachectic and Cachectic Patients with Pancreatic Ductal Adenocarcinoma.medRxiv : the preprint server for health sciences · 2025Article
- Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma.Communications medicine · 2025Article
- Nutritional Support for Gastrointestinal Cancer Patients: New (and Old) Frontiers in Management, a Narrative Review.Nutrients · 2025Review
- Circulating miRNAs Signature as a Predictor of Cachexia in Chronic Heart Failure: Diagnostic and Prognostic Implications.Journal of cardiovascular translational research · 2025Article
- Gut microbiota in cancer cachexia: a new frontier for research and therapy.Genes & nutrition · 2025Review
- Article
- Miraculin Can Contribute to a Reduction in Inflammatory Biomarkers and Cachexia in Malnourished Patients with Cancer and Taste Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Advanced High-Content Phenotypic Screening to Identify Drugs That Ameliorate the Inhibition of Skeletal Muscle Cell Differentiation Induced by Cancer Cachexia Serum.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer cachexia is a common condition in many cancer patients, particularly those with advanced disease. Cancer cachexia patients are generally less tolerant to chemotherapies and radiotherapies, largely limiting their treatment options. While the search for treatments of this condition are ongoing, standards for the efficacy of treatments have yet to be developed. Current diagnostic criteria for cancer cachexia are primarily based on loss of body mass and muscle function. However, these criteria are rather limiting, and in time, when weight loss is noticeable, it may be too late for treatment. Consequently, biomarkers for cancer cachexia would be valuable adjuncts to current diagnostic criteria, and for assessing potential treatments. Using high throughput methods such as "omics approaches", a plethora of potential biomarkers have been identified. This article reviews and summarizes current studies of biomarkers for cancer cachexia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.